May 2026

ORGAN TRANSPLANT

NOT ALL MISMATCHES CREATED EQUAL: WHY HLA-DQ DETAILS MAY MATTER MORE THAN PREVIOUSLY THOUGHT

Featuring: Anat Roitberg-Tambur, DMD, PhD
​
Read time: 2 minutes

Traditional donor-recipient matching treats human leukocyte antigen (HLA) mismatches as largely equivalent units, counted and summed to estimate immunologic risk. This study challenges that paradigm by asking if all HLA-DQ molecular mismatches are equally immunogenic.

Study investigators used adsorption/elution experiments with carefully selected HLA-DQ targets to dissect de novo donor-specific antibodies (dnDSA) at the level of individual epitopes. They focused on sera collected at the first detection of dnDSA, allowing them to capture the initial humoral response rather than late, heterogeneous patterns.

This approach enabled them to separate polyclonal sera into monospecific antibody signals, mapping which amino acid regions on HLA-DQ molecules are actually immunogenic in vivo.

The Findings to Know
  • Only a small subset of amino acid regions triggered the initial antibody response.
  • Alloimmunity begins with a restricted, high-immunogenicity epitope set, followed by epitope spreading to additional regions over time. 
  • The most immunogenic regions aligned with DQα chain-specific determinants and conventional serologic groupings.
  • Low-resolution typing may still capture meaningful biology. Interestingly, the key immunogenic regions correlated with antigen-level HLA typing, suggesting that some clinically actionable risk is already embedded in broader antigen categories.

How the Findings May Impact Clinical Practice
  • Expand donor options: Rather than minimizing total mismatch count, allocation algorithms could prioritize avoidance of high-immunogenicity DQ regions.
  • Improve risk stratification: Patients with high-risk “first-tier” mismatches could be identified pre-transplant, enabling: tailored induction strategies, closer post-transplant surveillance for dnDSA and earlier intervention.
  • Rationally minimize immunosuppression: Recipients without high-risk epitopes may represent a low-risk cohort for this.
  • Refine molecular matching tools: Current eplet-based and computational models may need recalibration to emphasize experimentally validated immunogenic regions, rather than all theoretical mismatches.
 
Why This Matters
HLA mismatch burden has long been associated with de novo Donor Specific Antibody formation, rejection and graft loss, but current tools often rely on aggregate molecular mismatch counts that assume additive, uniform risk.
​
This study’s findings reframes molecular matching from a question of how many mismatches to a question of which mismatches. 
Anat Roitberg-Tambur, DMD, PhD, ​Research Professor, Surgery (Organ Transplantation)

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like